Horien Biotech (7814) will officially list on the OTC market on July 15th. The company announced on July 9th that not only did its June revenue see a remarkable year-on-year increase of over 200%, but it also successfully obtained three Class 4 medical device marketing authorizations from the Thai Food and Drug Administration (TFDA) on July 7th.

 Horien Biotech stated that its consolidated revenue in June increased significantly by 209.29% compared to the same period last year; its cumulative revenue for the first six months of this year also increased by 55.78% compared to the same period last year, demonstrating a steady growth trend. The company stated that with the increasing penetration rate of its core technologies in regenerative medicine and clinical applications, the shipment volume of its core products is entering a period of explosive growth, resulting in strong operational momentum.

 Furthermore, Horien Biotech has also achieved a milestone breakthrough in expanding into the ASEAN market. On July 7th, the company officially received notification that its core R&D products, "Horien Extracellular Membrane," "Horien Collagen Bone Graft Matrix," and "Horien Collagen Matrix," have all passed the Thai FDA review and successfully obtained the highest level of medical device approval—Class 4—for market sales in Thailand.

 Horien Biotech pointed out that Thailand is a core market for medical aesthetics and high-end medical care in Southeast Asia. This successful acquisition of the highly challenging Class 4 market approval is not only an international affirmation of Horien Biotech's R&D capabilities and excellent manufacturing quality, but also will immediately translate into substantial orders for export to the Thai market, significantly contributing to future revenue.

 Listing on the OTC Market: Poised for the Next Golden Growth Period. Horien Biotech General Manager Ho Hsin-yu stated, "Today marks a significant milestone in Horien Biotech's development history. Listing not only introduces more capital market resources but also enhances the company's international visibility. Combined with recent strong revenue performance and the acquisition of advanced medical device certifications in Thailand, we are fully confident in propelling Taiwan's regenerative medicine technology onto a wider international stage, creating maximum value for our shareholders."

 The biotechnology and medical industry has been a star sector strongly supported by the OTC Market in recent years. Horien Biotech, leveraging its high-tech collagen biomedical material technology, laid a solid foundation during its emerging market phase. Now, upon listing, it simultaneously possesses two major engines: "revenue explosion" and "expansion into new overseas markets." The anticipated honeymoon period after listing and its medium- to long-term overseas expansion performance are highly promising for the market.

Report Link: